来那度胺联合地塞米松方案对复发难治多发性骨髓瘤的治疗作用并文献复习  

The efficacy and safety of treatment of relapsed and refractory multiple myeloma combining lenalidomide with dexamethasone

作　　者：洪铁艳[1] 余正平[2] 

机构地区：[1]东南大学医学院附属南京同仁医院血液肿瘤科,江苏南京211102 [2]东南大学医学院附属中大医院血液科,江苏南京210009

出　　处：《东南国防医药》2014年第6期597-599,618,共4页Military Medical Journal of Southeast China

摘　　要：目的：探讨来那度胺联合地塞米松治疗复发难治多发性骨髓瘤的疗效。方法10例复发难治多发性骨髓瘤患者，一线化疗耐受，予来那度胺联合地塞米松方案治疗。结果应用该方案后，患者疾病均得到控制，M蛋白与β2微球蛋白显著下降，无完全缓解，部分缓解率为40％；至2014年7月5例进展患者的无进展生存期为8个月（5～10个月）；其余5例病情均稳定。该方案相关毒性反应较轻，患者能够耐受。结论来那度胺联合地塞米松治疗复发难治多发性骨髓瘤患者，具有一定疗效，患者耐受性好。Objective This study was to determine the efficacy and safety of treatment of relapsed and refractory multiple my -eloma combining lenalidomide with dexamethasone .Methods 10 patients with relapsed and refractory multiple myeloma who failed for first line chemotherapy were treated with lenalidomide and dexamethasone based chemotherapy .Results After the treatment ,the levels of immunoglobulin and β2-microglobulin were reduced significantly .The disease control rate was 100%,the partial response rate was 40%.The disease progressed in 5 patients by July 2014,and the median duration of progression-free was 8 months （ range,5 -10 months）.Treatment-related toxicities were tolerant .Conclusion Lenalidomide-dexamethasone appears effective and tolerable in trea-ting patients with relapsed and refractory multiple myeloma .

关 键 词：来那度胺 复发难治多发性骨髓瘤 地塞米松 

分 类 号：R733.3[医药卫生—肿瘤]